Shares of Indivior PLC (NASDAQ:INDV - Get Free Report) saw strong trading volume on Thursday . 1,544,291 shares were traded during trading, an increase of 192% from the previous session's volume of 528,938 shares.The stock last traded at $8.88 and had previously closed at $8.58.
Analyst Ratings Changes
Several research analysts have weighed in on the company. RODMAN&RENSHAW upgraded Indivior to a "strong-buy" rating in a research report on Tuesday, January 28th. Rodman & Renshaw assumed coverage on Indivior in a research report on Tuesday, January 28th. They set a "buy" rating and a $16.00 price objective on the stock.
Read Our Latest Analysis on INDV
Indivior Stock Performance
The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -27.29 and a beta of 0.73. The firm has a fifty day moving average price of $11.09 and a 200-day moving average price of $10.65.
Indivior (NASDAQ:INDV - Get Free Report) last released its earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. The company had revenue of $298.00 million for the quarter, compared to analyst estimates of $262.35 million. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. On average, sell-side analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.
Institutional Trading of Indivior
Several large investors have recently modified their holdings of INDV. GF Fund Management CO. LTD. acquired a new stake in shares of Indivior during the 4th quarter worth $36,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Indivior in the fourth quarter valued at about $56,000. Lazard Asset Management LLC acquired a new stake in Indivior in the fourth quarter valued at about $57,000. Stifel Financial Corp acquired a new stake in Indivior in the third quarter valued at about $100,000. Finally, Melqart Asset Management UK Ltd acquired a new stake in Indivior in the third quarter valued at about $132,000. 60.33% of the stock is owned by institutional investors and hedge funds.
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
